Substudy - Evaluation of Patients With Iliac Vein Thrombosis

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

Patients with previous diagnosis of iliac vein thrombosis are enrolled in this registry. Using standardized questionnaire, clinical data detailing venous thromboembolism and contributing VTE risk factors are recorded. Results of technical and laboratory investigations including screening of thrombophilic disorders were additionally entered into the database.

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT04694248` - Anticoagulant Plus Antiplatelet Therapy Following Iliac Vein Stenting	N/A

NCT number	NCT03148548
Study type	Observational [Patient Registry]
Source	Cardioangiologisches Centrum Bethanien
Contact
Status	Completed
Phase
Start date	November 2016
Completion date	January 2018

Substudy - Evaluation of Patients With Iliac Vein Thrombosis

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms